Who is sponsoring NCT02852057?

NCT02852057 is sponsored by University of Florida.

What drugs are being tested in NCT02852057?

Interventions in NCT02852057: timolol maleate and dorzolamide hydrochloride.

Is NCT02852057 still recruiting?

NCT02852057 is currently completed. Last updated 2 December 2021.

Last reviewed 2021-12-02 · How we verify

NCT02852057

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses

Completed Phase 1 Last updated 2 December 2021

What this trial tests

Phase 1 trial testing timolol maleate and dorzolamide hydrochloride in Glaucoma in 2 participants. Completed in 10 August 2021.

Timeline

18 January 2018

Primary endpoint
10 August 2021

10 August 2021

Quick facts

Lead sponsor	University of Florida
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	18 January 2018
Primary completion	10 August 2021
Estimated completion	10 August 2021
Sites	1 location across United States

Drugs / interventions tested

timolol maleate and dorzolamide hydrochloride — full drug profile →

Conditions studied

Glaucoma — all drugs for Glaucoma →

Sponsor

University of Florida

Who can join

18 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study focuses on glaucoma therapy by drug eluting contact lenses. The contact lens will be loaded with timolol maleate and dorzolamide hydrochloride, both of which are commonly used ophthalmic drugs. Additionally, the lenses will contain vitamin E ((+) α-tocopherol) as an additive for achieving extended release of the drugs. This study is to assess the safety of the drug loaded contact lenses and the effectiveness. Effectiveness will be a drop in IOP after using the lenses.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging trends in long-acting sustained drug delivery for glaucoma management.
So YH, Mishra D, Gite S, Sonawane R, et al · · 2025 · cited 9× · PMID 39786666 · DOI 10.1007/s13346-024-01779-4
Advances in dorzolamide hydrochloride delivery: harnessing nanotechnology for enhanced ocular drug delivery in glaucoma management.
Pardeshi SR, Gholap AD, Hatvate NT, Gharat KD, et al · · 2024 · cited 4× · PMID 39656411 · DOI 10.1186/s11671-024-04154-x
Topical Gel/Microsphere Eyedrop for Combined Delivery of Brimonidine and Timolol: A Comparative Study With Traditional Eye Drops in Rabbits.
Fan X, Harding PA, Ziaei P, Chaudhry AB, et al · · 2025 · PMID 40693711 · DOI 10.1167/tvst.14.7.15

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02852057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 2 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02852057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing